European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Posted:
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection.
Based on research completed as part of a multi-year collaboration with Nokia Bell Labs, biomedical engineers at Duke University are developing a solution. Using a custom-built optical coherence tomography (OCT) imaging system together with artificial intelligence (AI) models grounded in…
Rare conditions in the ICU include both formally classified rare diseases and conditions that occur infrequently in critical care settings. These patients often face delayed diagnosis, limited specialist expertise and complex multisystem involvement, all of which contribute to poorer outcomes…
Attendees
Sponsors and Exhibitors
Contact us